Salute e Benessere
ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
JENA, Germany , Aug. 29, 2024 /PRNewswire/ -- ZEISS Medical Technology will showcase its latest cataract and corneal refractive workflow innovations at the European Society of Cataract and Refractive Surgeons (ESCRS) conference . ZEISS leads the industry as the first medical device manufacturer to offer in the CE markets. ZEISS is also celebrating its latest refractive milestone of performed with ZEISS SMILE and ZEISS SMILE pro. Building on its surgical technology, ZEISS will introduce its , as well as showcase its enhanced IOL portfolio including new trifocal IOL. Additionally, the company will show its latest AI technology within the ZEISS Cataract Workflow, including the CE-marked and the pending-CE-mark AI tool for improved pre-operative patient care. Both solutions highlight how digital technologies within the ZEISS Medical Ecosystem are continuing to set the pace for clinical workflow innovation and foretelling how AI technology will support more personalized patient care in the future.
"ZEISS continues to pave the way toward a future of truly personalized care through the development of some of the most advanced digital technologies and medical devices to meet the expanding needs of Europe's leading refractive and cataract surgeons," says Euan S. Thomson , Ph.D., President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit at ZEISS Medical Technology. "Using our latest offerings – including our VISUMAX 800 with SMILE pro, CIRRUS PathFinder and other data-driven AI tools – we're helping surgeons improve their workflow efficiencies and patient outcomes."
After more than 13 years of offering laser vision correction (LVC) solutions, including treatment options for myopia and presbyopia, ZEISS is once again reshaping the market with the introduction of lenticule extraction for hyperopic patients, with or without astigmatism, using the VISUMAX 800 . .
At ESCRS, ZEISS is also showcasing its complete ZEISS Corneal Refractive Workflow, now further enhanced by including computer-assisted cyclotorsion adjustment for the ZEISS VISUMAX 800, remote planning with the ZEISS Refractive Workplace, and the VISULYZE clinical nomogram and data analysis tool, all further enhancing the ZEISS digital portfolio and workflow solutions for corneal refractive. A recent study found that lenticule extraction using a ZEISS femtosecond laser provides an effective treatment method for the correction of compound hyperopic astigmatism, demonstrating a high level of efficacy, predictability, safety, and stability.
"ZEISS SMILE has become a benchmark for refractive surgery because of its quality and the results. In maybe 20 to 30 seconds, you change peoples' lives," says Dr. Andrea Russo , MD, Ph.D. Bio, Centro Oculistico Bresciano in Brescia, Italy .
Demonstrating its continued momentum in the LVC market, ZEISS announced that lenticule extraction solutions utilizing , marking a significant milestone for the company and proof of the growing international adoption of safe and effective lenticule extraction solutions. In 2011, ZEISS was the first medical device manufacturer to make lenticule extraction for laser vision correction commercially available, and ZEISS SMILE and ZEISS SMILE pro continue to be leading solutions trusted by surgeons for the technology's proven reliability and effective treatment with the VisuMax and VISUMAX 800 from ZEISS.
, which examined 237 patients who were treated with ZEISS SMILE pro using the ZEISS VISUMAX 800 femtosecond laser. Key findings will be highlighted in the following three abstracts being presented:
ZEISS is continuing to roll-out its expanded portfolio of high-end microscopes with the setting the pace in digital visualization with true color imaging and increased depth of field by nearly 60 percent. Additionally, the ZEISS ARTEVO 850 with CALLISTO eye features a redesigned intuitive user interface that centralizes all controls on a single touchscreen. The second latest addition to ZEISS's portfolio of optical surgical microscopes, the new elevates the surgical workflow by introducing advanced optical visualization technology, including new RGB LED illumination with adjustable light color temperature, as well as a 40 percent increase in resolution of data overlays provided in the eyepiece. The two devices are CE and FDA cleared and commercially available in all major markets.
Within the ZEISS Premium Cataract Workflow, the novel (IOL),
represents the best of ZEISS trifocal technology on a glistening-free hydrophobic c-loop platform. At ESCRS, new clinical results with the ZEISS AT ELANA 841P will be presented, highlighting excellent visual outcomes:
ZEISS continues to offer new digital tools to assist surgeons throughout their cataract workflow. The It is also compatible with the ZEISS IOLMaster 700 Total Keratometry (TK ). The ZEISS AI IOL Calculator is a data driven IOL power calculation algorithm and is a core feature of the ZEISS Cataract Workflow. It is optimized with a large amount of data for each IOL model it supports and therefore does not require IOL constants. It has shown great performance when applied to short eyes and outperformed most state-of-the-art formulas in short eyes.
"What's so unique about ZEISS AI IOL Calculator is that it is IOL specific but does not require IOL constants. We rely on the ZEISS AI IOL Calculator for the entire spectrum of axial lengths, and it especially shines in short eyes," said Dr. Douglas D. Koch , M.D., Baylor College of Medicine , Houston, Texas , USA.
As an example of the company's digital diagnostic OCT leadership, ZEISS will also show , a fully integrated AI decision support tool that uses proprietary deep learning algorithms, trained by retina specialists, to automatically identify abnormal macular OCT B-scans assisting with pre-surgical assessment of the retina and optimizing outcomes. ZEISS CIRRUS PathFinder will be available in select markets subject to local regulatory clearances and is currently pending CE mark.
In addition, ZEISS will demonstrate how post-surgery review, analysis and sharing of surgery videos is now made possible with a new spatial computing app for reviewing 3D videos, based on the ZEISS Surgery Optimizer. This exclusive experience on Apple Vision Pro represents an entirely new way for ophthalmologists to review 3D videos pre-recorded with ZEISS digital surgical microscopes. Using an Apple Vision Pro, surgeons can review 2D or 3D surgery videos, scans of the eye, patient information and much more simultaneously; a comprehensive spatial computing experience easily controlled by the user's eyes, hands, and voice.
ZEISS will showcase its latest innovations across the cataract and corneal refractive workflows at ESCRS in Hall 7 at booth D23 from Sept. 6-10 , in Barcelona, Spain .
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.meditec@zeiss.com
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group's head office is located in Jena, Germany , and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA , Japan , Spain and France . The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China , strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
View original content: https://www.prnewswire.co.uk/news-releases/zeiss-innovation-paves-way-to-more-personalized-patient-care-with-cutting-edge-ai-technology-and-industry-leading-surgical-solutions-302233672.html